Radiotherapy for cervical cancer with high-dose rate brachytherapy - correlation between tumor size, dose and failure

Hisao Ito, Shoji Kutuki, Iku Nishiguchi, Naoyuki Shigematsu, Tohru Kuribayashi, Minoru Uematsu, Toshitake Nakayama, Wei Jei Ka, Kazuhiko Takemasa, Yutaka Ando, Atsushi Kubo

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

This is a retrospective analysis of 659 patients with cervical squamous cell carcinoma with a minimum follow-up of 2 years at Keio University Hospital between May 1974 and March 1990. All patients were treated with external radiation (50 Gy) and high-dose rate (HDR) intracavitary brachytherapy (20-34 Gy). The 5-year survival rates in each stage gradually decreased with the advance of the stage (I, 84%; II, 7I%; III, 47%; and IVa, 12%). When 366 patients with stage III were classified into three groups according to tumor size, i.e. small (S, I02 patients), medium (M, I45) and large (L, 119), a survival gradient of small > medium > large was demonstrated and the differences between them were significant. At follow-up visits conducted between 1 and 2 months after completion of treatment, 135 patients (20%) had physical indications of residual disease. The larger the tumor size, the more likely was residual disease by 2 months. The patients with residual disease had a significantly higher rate of the pelvic failure than those without it. There was no significant correlation between radiation doses by RALS and pelvic failure rates, except in the stage III-L group. In the stage III-L group, intracavitary doses of 24 Gy or less to point A could be correlated with the higher pelvic failure rate and the lower survival rate, in contrast to doses of 27 Gy or more. The incidence of major rectosigmoid complications was 11.8% with doses of 24 Gy or less to point A, 8.1% with 27 Gy and I9.2% with doses of 30 Gy or more. The incidence of major rectosigmoid complications is likely to increase with doses higher than 30 Gy. The incidence of severe urinary complications was less than 1.5% with doses between 20 and 34 Gy. It was concluded that 27 Gy by HDR brachytherapy may be recommended for cervical cancer except for larger tumors or tumor that did not regress promptly. Such poor-prognosis patients should be targeted for the early adjuvant or salvage therapy.

Original languageEnglish
Pages (from-to)240-247
Number of pages8
JournalRadiotherapy and Oncology
Volume31
Issue number3
DOIs
Publication statusPublished - 1994

Fingerprint

Brachytherapy
Uterine Cervical Neoplasms
Radiotherapy
Neoplasms
Incidence
Survival Rate
Radiation Dosage
Salvage Therapy
Secondary Prevention
Squamous Cell Carcinoma
Radiation
Survival

Keywords

  • Cervical cancer
  • High dose-rate brachytherapy
  • Metastasis
  • Recurrence
  • Residual tumor

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Cite this

Radiotherapy for cervical cancer with high-dose rate brachytherapy - correlation between tumor size, dose and failure. / Ito, Hisao; Kutuki, Shoji; Nishiguchi, Iku; Shigematsu, Naoyuki; Kuribayashi, Tohru; Uematsu, Minoru; Nakayama, Toshitake; Ka, Wei Jei; Takemasa, Kazuhiko; Ando, Yutaka; Kubo, Atsushi.

In: Radiotherapy and Oncology, Vol. 31, No. 3, 1994, p. 240-247.

Research output: Contribution to journalArticle

Ito, H, Kutuki, S, Nishiguchi, I, Shigematsu, N, Kuribayashi, T, Uematsu, M, Nakayama, T, Ka, WJ, Takemasa, K, Ando, Y & Kubo, A 1994, 'Radiotherapy for cervical cancer with high-dose rate brachytherapy - correlation between tumor size, dose and failure', Radiotherapy and Oncology, vol. 31, no. 3, pp. 240-247. https://doi.org/10.1016/0167-8140(94)90429-4
Ito, Hisao ; Kutuki, Shoji ; Nishiguchi, Iku ; Shigematsu, Naoyuki ; Kuribayashi, Tohru ; Uematsu, Minoru ; Nakayama, Toshitake ; Ka, Wei Jei ; Takemasa, Kazuhiko ; Ando, Yutaka ; Kubo, Atsushi. / Radiotherapy for cervical cancer with high-dose rate brachytherapy - correlation between tumor size, dose and failure. In: Radiotherapy and Oncology. 1994 ; Vol. 31, No. 3. pp. 240-247.
@article{1f0ff1a482ec4f2d93e39750424db6d0,
title = "Radiotherapy for cervical cancer with high-dose rate brachytherapy - correlation between tumor size, dose and failure",
abstract = "This is a retrospective analysis of 659 patients with cervical squamous cell carcinoma with a minimum follow-up of 2 years at Keio University Hospital between May 1974 and March 1990. All patients were treated with external radiation (50 Gy) and high-dose rate (HDR) intracavitary brachytherapy (20-34 Gy). The 5-year survival rates in each stage gradually decreased with the advance of the stage (I, 84{\%}; II, 7I{\%}; III, 47{\%}; and IVa, 12{\%}). When 366 patients with stage III were classified into three groups according to tumor size, i.e. small (S, I02 patients), medium (M, I45) and large (L, 119), a survival gradient of small > medium > large was demonstrated and the differences between them were significant. At follow-up visits conducted between 1 and 2 months after completion of treatment, 135 patients (20{\%}) had physical indications of residual disease. The larger the tumor size, the more likely was residual disease by 2 months. The patients with residual disease had a significantly higher rate of the pelvic failure than those without it. There was no significant correlation between radiation doses by RALS and pelvic failure rates, except in the stage III-L group. In the stage III-L group, intracavitary doses of 24 Gy or less to point A could be correlated with the higher pelvic failure rate and the lower survival rate, in contrast to doses of 27 Gy or more. The incidence of major rectosigmoid complications was 11.8{\%} with doses of 24 Gy or less to point A, 8.1{\%} with 27 Gy and I9.2{\%} with doses of 30 Gy or more. The incidence of major rectosigmoid complications is likely to increase with doses higher than 30 Gy. The incidence of severe urinary complications was less than 1.5{\%} with doses between 20 and 34 Gy. It was concluded that 27 Gy by HDR brachytherapy may be recommended for cervical cancer except for larger tumors or tumor that did not regress promptly. Such poor-prognosis patients should be targeted for the early adjuvant or salvage therapy.",
keywords = "Cervical cancer, High dose-rate brachytherapy, Metastasis, Recurrence, Residual tumor",
author = "Hisao Ito and Shoji Kutuki and Iku Nishiguchi and Naoyuki Shigematsu and Tohru Kuribayashi and Minoru Uematsu and Toshitake Nakayama and Ka, {Wei Jei} and Kazuhiko Takemasa and Yutaka Ando and Atsushi Kubo",
year = "1994",
doi = "10.1016/0167-8140(94)90429-4",
language = "English",
volume = "31",
pages = "240--247",
journal = "Radiotherapy and Oncology",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Radiotherapy for cervical cancer with high-dose rate brachytherapy - correlation between tumor size, dose and failure

AU - Ito, Hisao

AU - Kutuki, Shoji

AU - Nishiguchi, Iku

AU - Shigematsu, Naoyuki

AU - Kuribayashi, Tohru

AU - Uematsu, Minoru

AU - Nakayama, Toshitake

AU - Ka, Wei Jei

AU - Takemasa, Kazuhiko

AU - Ando, Yutaka

AU - Kubo, Atsushi

PY - 1994

Y1 - 1994

N2 - This is a retrospective analysis of 659 patients with cervical squamous cell carcinoma with a minimum follow-up of 2 years at Keio University Hospital between May 1974 and March 1990. All patients were treated with external radiation (50 Gy) and high-dose rate (HDR) intracavitary brachytherapy (20-34 Gy). The 5-year survival rates in each stage gradually decreased with the advance of the stage (I, 84%; II, 7I%; III, 47%; and IVa, 12%). When 366 patients with stage III were classified into three groups according to tumor size, i.e. small (S, I02 patients), medium (M, I45) and large (L, 119), a survival gradient of small > medium > large was demonstrated and the differences between them were significant. At follow-up visits conducted between 1 and 2 months after completion of treatment, 135 patients (20%) had physical indications of residual disease. The larger the tumor size, the more likely was residual disease by 2 months. The patients with residual disease had a significantly higher rate of the pelvic failure than those without it. There was no significant correlation between radiation doses by RALS and pelvic failure rates, except in the stage III-L group. In the stage III-L group, intracavitary doses of 24 Gy or less to point A could be correlated with the higher pelvic failure rate and the lower survival rate, in contrast to doses of 27 Gy or more. The incidence of major rectosigmoid complications was 11.8% with doses of 24 Gy or less to point A, 8.1% with 27 Gy and I9.2% with doses of 30 Gy or more. The incidence of major rectosigmoid complications is likely to increase with doses higher than 30 Gy. The incidence of severe urinary complications was less than 1.5% with doses between 20 and 34 Gy. It was concluded that 27 Gy by HDR brachytherapy may be recommended for cervical cancer except for larger tumors or tumor that did not regress promptly. Such poor-prognosis patients should be targeted for the early adjuvant or salvage therapy.

AB - This is a retrospective analysis of 659 patients with cervical squamous cell carcinoma with a minimum follow-up of 2 years at Keio University Hospital between May 1974 and March 1990. All patients were treated with external radiation (50 Gy) and high-dose rate (HDR) intracavitary brachytherapy (20-34 Gy). The 5-year survival rates in each stage gradually decreased with the advance of the stage (I, 84%; II, 7I%; III, 47%; and IVa, 12%). When 366 patients with stage III were classified into three groups according to tumor size, i.e. small (S, I02 patients), medium (M, I45) and large (L, 119), a survival gradient of small > medium > large was demonstrated and the differences between them were significant. At follow-up visits conducted between 1 and 2 months after completion of treatment, 135 patients (20%) had physical indications of residual disease. The larger the tumor size, the more likely was residual disease by 2 months. The patients with residual disease had a significantly higher rate of the pelvic failure than those without it. There was no significant correlation between radiation doses by RALS and pelvic failure rates, except in the stage III-L group. In the stage III-L group, intracavitary doses of 24 Gy or less to point A could be correlated with the higher pelvic failure rate and the lower survival rate, in contrast to doses of 27 Gy or more. The incidence of major rectosigmoid complications was 11.8% with doses of 24 Gy or less to point A, 8.1% with 27 Gy and I9.2% with doses of 30 Gy or more. The incidence of major rectosigmoid complications is likely to increase with doses higher than 30 Gy. The incidence of severe urinary complications was less than 1.5% with doses between 20 and 34 Gy. It was concluded that 27 Gy by HDR brachytherapy may be recommended for cervical cancer except for larger tumors or tumor that did not regress promptly. Such poor-prognosis patients should be targeted for the early adjuvant or salvage therapy.

KW - Cervical cancer

KW - High dose-rate brachytherapy

KW - Metastasis

KW - Recurrence

KW - Residual tumor

UR - http://www.scopus.com/inward/record.url?scp=0028307801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028307801&partnerID=8YFLogxK

U2 - 10.1016/0167-8140(94)90429-4

DO - 10.1016/0167-8140(94)90429-4

M3 - Article

VL - 31

SP - 240

EP - 247

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

SN - 0167-8140

IS - 3

ER -